Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Fortress Biotech Inc (NASDAQ: FBIO) was $1.91 for the day, up 1.60% from the previous closing price of $1.88. In other words, the price has increased by $1.60 from its previous closing price. On the day, 0.63 million shares were traded. FBIO stock price reached its highest trading level at $2.05 during the session, while it also had its lowest trading level at $1.85.
Ratios:
Our analysis of FBIO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.55 and its Current Ratio is at 1.72. In the meantime, Its Debt-to-Equity ratio is 3.34 whereas as Long-Term Debt/Eq ratio is at 3.16.
On August 04, 2022, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $6.
On October 02, 2020, The Benchmark Company started tracking the stock assigning a Buy rating and target price of $9.The Benchmark Company initiated its Buy rating on October 02, 2020, with a $9 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 29 ’25 when Fortress Biotech, Inc. sold 100,000 shares for $1.29 per share. The transaction valued at 129,000 led to the insider holds 6,122,249 shares of the business.
ROSENWALD LINDSAY A MD bought 763,359 shares of FBIO for $1,404,581 on Sep 23 ’24. The PRESIDENT, CEO & CHAIRMAN now owns 3,657,264 shares after completing the transaction at $1.84 per share. On Jul 11 ’24, another insider, ROSENWALD LINDSAY A MD, who serves as the President, CEO & Chairman of the company, bought 5,000 shares for $7.48 each. As a result, the insider paid 37,418 and bolstered with 127,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FBIO now has a Market Capitalization of 56478508 and an Enterprise Value of 48136052. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.98 while its Price-to-Book (P/B) ratio in mrq is 2.54. Its current Enterprise Value per Revenue stands at 0.833 whereas that against EBITDA is -0.571.
Stock Price History:
The Beta on a monthly basis for FBIO is 1.76, which has changed by 0.11046517 over the last 52 weeks, in comparison to a change of 0.11708844 over the same period for the S&P500. Over the past 52 weeks, FBIO has reached a high of $2.89, while it has fallen to a 52-week low of $1.33. The 50-Day Moving Average of the stock is 5.30%, while the 200-Day Moving Average is calculated to be 8.42%.
Shares Statistics:
FBIO traded an average of 195.08K shares per day over the past three months and 231590 shares per day over the past ten days. A total of 29.55M shares are outstanding, with a floating share count of 21.13M. Insiders hold about 28.55% of the company’s shares, while institutions hold 16.61% stake in the company. Shares short for FBIO as of 1749772800 were 3294028 with a Short Ratio of 16.89, compared to 1747267200 on 3509189. Therefore, it implies a Short% of Shares Outstanding of 3294028 and a Short% of Float of 14.12.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current market rating for Fortress Biotech Inc (FBIO) reflects the collective analysis of 1 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.24 and low estimates of -$0.24.
Analysts are recommending an EPS of between -$1.2 and -$1.2 for the fiscal current year, implying an average EPS of -$1.2. EPS for the following year is -$0.45, with 1.0 analysts recommending between -$0.45 and -$0.45.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 2 analysts. It ranges from a high estimate of $14.63M to a low estimate of $14.44M. As of the current estimate, Fortress Biotech Inc’s year-ago sales were $14.9MFor the next quarter, 2 analysts are estimating revenue of $19.29M. There is a high estimate of $19.88M for the next quarter, whereas the lowest estimate is $18.7M.
A total of 2 analysts have provided revenue estimates for FBIO’s current fiscal year. The highest revenue estimate was $103.09M, while the lowest revenue estimate was $68.34M, resulting in an average revenue estimate of $85.71M. In the same quarter a year ago, actual revenue was $57.67MBased on 2 analysts’ estimates, the company’s revenue will be $124.06M in the next fiscal year. The high estimate is $146.76M and the low estimate is $101.36M.
